Rocket Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.29 billion
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Rocket Pharmaceuticals Inc had its IPO on 2015-02-18 under the ticker symbol RCKT.
The company operates in the Healthcare sector and Biotechnology industry. Rocket Pharmaceuticals Inc has a staff strength of 240 employees.
Shares of Rocket Pharmaceuticals Inc opened at $15.63 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $15.27 - $15.75, and closed at $15.29.
This is a -1.55% slip from the previous day's closing price.
A total volume of 923,210 shares were traded at the close of the day’s session.
In the last one week, shares of Rocket Pharmaceuticals Inc have slipped by -4.44%.
Rocket Pharmaceuticals Inc's Key Ratios
Rocket Pharmaceuticals Inc has a market cap of $1.29 billion, indicating a price to book ratio of 4.0724 and a price to sales ratio of 0.
In the last 12-months Rocket Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-253559008. The EBITDA ratio measures Rocket Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Rocket Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -36.09% with a return of equity of -62.86%.
In Q2, Rocket Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Rocket Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rocket Pharmaceuticals Inc’s profitability.
Rocket Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -6.3916. Its price to sales ratio in the trailing 12-months stood at 0.
Rocket Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $461.78 million
- Total Liabilities
- $34.35 million
- Operating Cash Flow
- $31.21 million
- Capital Expenditure
- $4.15 million
- Dividend Payout Ratio
Rocket Pharmaceuticals Inc ended 2023 with $461.78 million in total assets and $0 in total liabilities. Its intangible assets were valued at $461.78 million while shareholder equity stood at $402.97 million.
Rocket Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $34.35 million in other current liabilities, 805000.00 in common stock, $-837811000.00 in retained earnings and $39.15 million in goodwill. Its cash balance stood at $45.08 million and cash and short-term investments were $307.04 million. The company’s total short-term debt was $2,993,000 while long-term debt stood at $0.
Rocket Pharmaceuticals Inc’s total current assets stands at $312.07 million while long-term investments were $0.00 and short-term investments were $261.96 million. Its net receivables were $0 compared to accounts payable of $31.35 million and inventory worth $0.
In 2023, Rocket Pharmaceuticals Inc's operating cash flow was $31.21 million while its capital expenditure stood at $4.15 million.
Comparatively, Rocket Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Rocket Pharmaceuticals Inc stock is currently trading at $15.29 per share. It touched a 52-week high of $24.53 and a 52-week low of $24.53. Analysts tracking the stock have a 12-month average target price of $52.6.
Its 50-day moving average was $17.27 and 200-day moving average was $19.2 The short ratio stood at 13.37 indicating a short percent outstanding of 0%.
Around 375.6% of the company’s stock are held by insiders while 10017.5% are held by institutions.
Frequently Asked Questions About Rocket Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.